N@N

Halozyme to Present at J.P. Morgan Healthcare Conference on January 13

^{Published on 2010-01-06 21:00:12 - Market Wire}
 

SAN DIEGO--([ BUSINESS WIRE ])--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the [ extracellular matrix ], today announced its participation in the 28^th Annual J.P. Morgan Healthcare Conference to be held on January 11-14, 2010 in San Francisco. Jonathan Lim, M.D., president and CEO, will present an overview of Halozyme and its product development [ pipeline ] on Wednesday, January 13, 2010 at 11:30 a.m. PST (2:30 p.m. EST).

To listen to the audio webcast of the presentation live or after the event, please visit the company's Web site at [ www.halozyme.com ]. The replay will be available for 90 days after the presentation.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze^™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze technology to Baxter's biological therapeutic compound, GAMMAGARD Liquid^®. The product candidates in Halozyme's research pipeline target multiple areas of significant unmet medical need. For more information visit [ www.halozyme.com ].